13th Annual Global Embolization Symposium & Technologies
Purpose : The goal of the study is to assess whether DEBIRI beads size affects patient clinical outcomes.
Material and Methods : Between Mar. 2009 and Jan. 2018 all consecutive patients referred to DEBIRI were included in this observational study. Patients were referred to 75-100μm or 100-300μm irinotecan loaded DC-beads. All patient clinical outcomes were monitored. Liver tumor response rate at 3 months (RECIST 1.0), liver, overall progression free survival, and overall survival were estimated with Kaplan Meier curves.
Results : 84 colorectal liver-dominant consecutive patients in a progressive disease (RECIST 1.0) status underwent 232 DEBIRI sessions. All patients had prior systemic treatment, from 2 to 5 lines of chemotherapy including oxaliplatin and irinotecan based chemotherapies. 54 and 30 patients received respectively 75-100μm or 100-300μm DC beads loaded with 100mg of irinotecan per vial. Systemic chemotherapy was given 15 days following DEBIRI. The 3 month overall tumor response was: progressive disease n=15 (18%); stable disease n=46 (55%) and partial response n=23 (27%). No complete response was observed. The median liver-PFS was 230 days (+-141). The median overall survival was 445 days (+-229). When analyzing liver-PFS and overall survival by beads size groups, no significant difference was observed. (figure 1).
Conclusions : DEBIRI with 75-100μm or 100-300μm beads did not show significant difference in patient outcome.